Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14:417–33.

CAS  PubMed  PubMed Central  Google Scholar 

Narayanan S, Cai C, Assaraf YG, Guo H, Cui Q, Wei L, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020;48:100663.

PubMed  Google Scholar 

Curran MP, Mckeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs. 2009;69:859–88.

CAS  PubMed  Google Scholar 

Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20:1242–53.

CAS  PubMed  Google Scholar 

Cockram PE, Kist M, Prakash S, Chen S, Wertz IE, Vucic D. Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ. 2021;28:591–605.

CAS  PubMed  PubMed Central  Google Scholar 

Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018;17:57–78.

CAS  PubMed  Google Scholar 

Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842–62.

CAS  PubMed  Google Scholar 

Ren J, Yu P, Liu S, Li R, Niu X, Chen Y, et al. Deubiquitylating enzymes in cancer and immunity. Adv Sci (Weinh). 2023;10:e2303807.

PubMed  Google Scholar 

Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669–85.

CAS  PubMed  Google Scholar 

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80.

PubMed  Google Scholar 

Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.

CAS  PubMed  Google Scholar 

Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016;16:412.

PubMed  PubMed Central  Google Scholar 

Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329:1271–82.

CAS  PubMed  PubMed Central  Google Scholar 

Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361–75.

PubMed  PubMed Central  Google Scholar 

Zhou Y, Wu J, Fu X, Du W, Zhou L, Meng X, et al. OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer. Mol Cancer. 2014;13:258.

PubMed  PubMed Central  Google Scholar 

Zhong J, Zhao M, Ma Y, Luo Q, Liu J, Wang J, et al. UCHL1 acts as a colorectal cancer oncogene via activation of the beta-catenin/TCF pathway through its deubiquitinating activity. Int J Mol Med. 2012;30:430–6.

CAS  PubMed  Google Scholar 

Trulsson F, Akimov V, Robu M, van Overbeek N, Berrocal DAP, Shah RG, et al. Deubiquitinating enzymes and the proteasome regulate preferential sets of ubiquitin substrates. Nat Commun. 2022;13:2736.

CAS  PubMed  PubMed Central  Google Scholar 

He L, Yu C, Qin S, Zheng E, Liu X, Liu Y, et al. The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity. Mol Cell. 2023;83:4000–16.

CAS  PubMed  Google Scholar 

Wang F, Ning S, Yu B, Wang Y. USP14: structure, function, and target inhibition. Front Pharmacol. 2021;12:801328.

CAS  PubMed  Google Scholar 

Wang D, Ma H, Zhao Y, Zhao J. Ubiquitin-specific protease 14 is a new therapeutic target for the treatment of diseases. J Cell Physiol. 2021;236:3396–405.

CAS  PubMed  Google Scholar 

Liu B, Chen J, Zhang S. Emerging role of ubiquitin-specific protease 14 in oncogenesis and development of tumor: therapeutic implication. Life Sci. 2019;239:116875.

CAS  PubMed  Google Scholar 

Shi D, Wu X, Jian Y, Wang J, Huang C, Mo S, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun. 2022;13:5644.

CAS  PubMed  PubMed Central  Google Scholar 

Du X, Ke S, Liang X, Gao J, Xie X, Qi L, et al. USP14 promotes colorectal cancer progression by targeting JNK for stabilization. Cell Death Dis. 2023;14:56.

CAS  PubMed  PubMed Central  Google Scholar 

Lu B, Sun Y, Chen B, Yang B, He Q, Li J, et al. ZDHHC20-driven s-palmitoylation of CD80 is required for its costimulatory function. Acta Pharmacol Sin. 2024;45:1214–23.

CAS  PubMed  PubMed Central  Google Scholar 

Yuan M, Chen X, Sun Y, Jiang L, Xia Z, Ye K, et al. ZDHHC12-mediated claudin-3 s-palmitoylation determines ovarian cancer progression. Acta Pharm Sin B. 2020;10:1426–39.

CAS  PubMed  PubMed Central  Google Scholar 

Xiang J, Zhang N, Du A, Li J, Luo M, Wang Y, et al. A ubiquitin-dependent switch on MEF2d senses pro-metastatic niche signals to facilitate intrahepatic metastasis of liver cancer. Adv Sci (Weinh). 2023;10:e2305550.

PubMed  Google Scholar 

Zhao C, Gong J, Bai Y, Yin T, Zhou M, Pan S, et al. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Cell Death Differ. 2023;30:1–15.

PubMed  Google Scholar 

Xia X, Huang C, Liao Y, Liu Y, He J, Guo Z, et al. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. J Exp Clin Cancer Res. 2019;38:220.

PubMed  PubMed Central  Google Scholar 

Lee B, Lee MJ, Park S, Oh D, Elsasser S, Chen P, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010;467:179–84.

CAS  PubMed  PubMed Central  Google Scholar 

Tian Z, D’Arcy P, Wang X, Ray A, Tai Y, Hu Y, et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014;123:706–16.

CAS  PubMed  PubMed Central  Google Scholar 

Xu D, Shan B, Lee B, Zhu K, Zhang T, Sun H, et al. Phosphorylation and activation of ubiquitin-specific protease-14 by akt regulates the ubiquitin-proteasome system. Elife. 2015;4:e10510.

PubMed  PubMed Central  Google Scholar 

Yuan T, Zeng C, Liu J, Zhao C, Ge F, Li Y, et al. Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (liver kinase b1) activity. Signal Transduct Target Ther. 2024;9:11.

CAS  PubMed  PubMed Central  Google Scholar 

Jadav SS, Sinha BN, Hilgenfeld R, Pastorino B, de Lamballerie X, Jayaprakash V. Thiazolidone derivatives as inhibitors of chikungunya virus. Eur J Med Chem. 2015;89:172–8.

CAS  PubMed  Google Scholar 

Huynh K, Partch CL. Analysis of protein stability and ligand interactions by thermal shift assay. Curr Protoc Protein Sci. 2015;79:28–9.

PubMed Central  Google Scholar 

Abo M, Li C, Weerapana E. Isotopically-labeled iodoacetamide-alkyne probes for quantitative cysteine-reactivity profiling. Mol Pharmacol. 2018;15:743–9.

CAS  Google Scholar 

Xu D, Shan B, Sun H, Xiao J, Zhu K, Xie X, et al. USP14 regulates autophagy by suppressing k63 ubiquitination of beclin 1. Genes Dev. 2016;30:1718–30.

CAS  PubMed  PubMed Central  Google Scholar 

Lv C, Wang S, Lin L, Wang C, Zeng K, Meng Y, et al. USP14 maintains HIF1-alpha stabilization via its deubiquitination activity in hepatocellular carcinoma. Cell Death Dis. 2021;12:803.

CAS  PubMed  PubMed Central  Google Scholar